Guhan Pharmaceutical Group Co

Guhan Pharmaceutical Group Co EBIT Margin

The EBIT Margin (Operating Margin) of Guhan Pharmaceutical Group Co (000590.SZ) as of Oct 30, 2026 is -13.85 %. In the previous year, EBIT Margin (Operating Margin) was -49.15 % — a change of -71.82% (higher).

EBIT Margin

-13.85 %

YoY

-71.82%

Last updated:

EBIT Margin (Operating Margin) of Guhan Pharmaceutical Group Co is 2025 -13.85 % . EBIT Margin (Operating Margin) of Guhan Pharmaceutical Group Co was 2024 -49.15 % . It decreases by -71.82% higher compared to the previous year.

Guhan Pharmaceutical Group Co's operating (EBIT) margin stands at -13.9%, down from 14.1% several years earlier.

The Guhan Pharmaceutical Group Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-18.99 CNY
Jan 1, 2019
16.54 CNY
Jan 1, 2020
10.10 CNY
Jan 1, 2021
14.08 CNY
Jan 1, 2022
6.47 CNY
Jan 1, 2023
5.50 CNY
Jan 1, 2024
-49.15 CNY
Jan 1, 2025
-13.85 CNY
The Guhan Pharmaceutical Group Co EBIT Margin history
YEAREBIT MarginYoY
-13.85 %-71.82%
-49.15 %-993.20%
5.50 %-14.93%
6.47 %-54.07%
14.08 %+39.41%
10.10 %-38.93%
16.54 %-187.10%
-18.99 %-349.19%
7.62 %-64.62%
21.54 %+117.83%
9.89 %-128.77%
-34.37 %+6,749.19%
-0.50 %-486.86%
0.13 %-47.09%
0.25 %+23.83%
0.20 %-175.62%
-0.26 %-374.03%
0.10 %-43.75%
0.17 %+1,977.24%
0.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Guhan Pharmaceutical Group Co Stock analysis

What does Guhan Pharmaceutical Group Co do? Tus-Pharmaceutical Group Co., Ltd. generates revenue through the research and development, production, and sales of Chinese patent medicine and western medicine preparations. The company offers Chinese healthcare products, cold treatment medicines, and anti hyperlipemia medicines, alongside western medicine products such as clindamycin phosphate for injection, lomefloxacin hydrochloride for injection, and levofloxacin lactate for injection. Domestic markets are the primary sales channel for all products. The firm's revenue streams are derived from the sale of these pharmaceutical products to domestic customers. The company focuses on Chinese patent medicine, including healthcare products, cold treatment remedies, and anti hyperlipemia treatments. Western medicine preparations like clindamycin phosphate for injection, lomefloxacin hydrochloride for injection, and levofloxacin lactate for injection form a significant part of its product portfolio. These products are distributed exclusively within China, targeting domestic consumers and healthcare providers. Tus-Pharmaceutical Group Co., Ltd. serves domestic markets with its range of Chinese and western medicines. The company's product lines include Chinese healthcare products, cold treatment medicines, anti hyperlipemia medicines, and specific western medicine injections. Sales are conducted within China, with no mention of international distribution. The firm's revenue is generated through the direct sale of these pharmaceutical products to domestic buyers. Guhan Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guhan Pharmaceutical Group Co stock

EBIT Margin (Operating Margin) of Guhan Pharmaceutical Group Co is -13.85 % in 2025.

EBIT Margin (Operating Margin) of Guhan Pharmaceutical Group Co changed from -49.15 % to -13.85 %, representing a -71.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Guhan Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Guhan Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Guhan Pharmaceutical Group Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Guhan Pharmaceutical Group Co